There is debate regarding the optimal time to initiate antiretroviral therapy (ART) in resource-limited settings. The research goal of Dr. Serena Koenig, an infectious disease fellow and associate physician in the Division of Social Medicine and Health Inequalities at Brigham and Women's Hospital, is to determine the optimal time to initiate ART in patients with symptomatic HIV disease in Haiti using a decision modeling approach to incorporate complex trade-offs among clinical benefits, risk of toxicity, and financial cost. She will carry out the proposed health outcomes study in parallel with a randomized control trial that will be conducted by the GHESKIO research center in Port au Prince to compare survival and TB outcomes for early versus delayed treatment of patients with pre-AIDS symptomatic HIV disease. She will be mentored by Drs. Sue Goldie, Warren Johnson, and Jean William Pape. This research plan is composed of three specific aims: 1. To measure quality of life and adherence to ART among patients in the early and delayed treatment groups in the clinical trial, and to conduct an interview study of patients and other members of the Haitian community to compare the values they place on health at different stages of HIV disease. 2. To perform a cost analysis of HIV care in Haiti using clinical trial data and retrospective data collected on patients treated at GHESKIO and elsewhere in Haiti. This analysis will estimate the initial, induced, and averted costs of health-care resources over time for early versus delayed ART. 3. To conduct a cost-effectiveness analysis of early versus delayed ART in Haiti from a societal perspective. Outcome measures will include life expectancy, lifetime total direct medical costs, and costeffectiveness in dollars per quality-adjusted life-year gained and in disability-adjusted life-year gained. Results will be stratified based on the presence or absence of active tuberculosis (TB) infection and sensitivity analyses will examine the impact of adherence rates. ? ?

Agency
National Institute of Health (NIH)
Institute
Fogarty International Center (FIC)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01TW007142-03
Application #
7110292
Study Section
Special Emphasis Panel (ZRG1-ICP-3 (03))
Program Officer
Jessup, Christine
Project Start
2004-09-01
Project End
2008-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
3
Fiscal Year
2006
Total Cost
$128,120
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Noel, Edva; Esperance, Morgan; McLaughlin, Megan et al. (2013) Attrition from HIV testing to antiretroviral therapy initiation among patients newly diagnosed with HIV in Haiti. J Acquir Immune Defic Syndr 62:e61-9
Koenig, Serena P; Rodriguez, Luis A; Bartholomew, Courtenay et al. (2012) Long-term antiretroviral treatment outcomes in seven countries in the Caribbean. J Acquir Immune Defic Syndr 59:e60-71
Koenig, Serena P; Bang, Heejung; Severe, Patrice et al. (2011) Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. PLoS Med 8:e1001095
Koenig, S; Ivers, Lc; Pace, S et al. (2010) Successes and challenges of HIV treatment programs in Haiti: aftermath of the earthquake. HIV Ther 4:145-160
Koenig, Serena P; Schackman, Bruce R; Riviere, Cynthia et al. (2010) Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Clin Infect Dis 51:600-8
Koenig, Serena P; Riviere, Cynthia; Leger, Paul et al. (2009) High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 48:829-31
Koenig, Serena P; Kuritzkes, Daniel R; Hirsch, Martin S et al. (2006) Monitoring HIV treatment in developing countries. BMJ 332:602-4